The value of additional MR-Ultrasound fusion guided biopsies to standard Navigo*-based biopsies in the diagnosis of prostate cancer

The value of additional MR-Ultrasound fusion guided biopsies to standard Navigo*-based biopsies in the diagnosis of prostate cancer - The value of additional MR-Ultrasound fusion guided biopsies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON43620

Enrollment

100

Registered

2015-11-11

Start date

2016-01-12

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate malignancy

Interventions

There will be no intervention group, it will be an in-patient control study.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Men aged 50-65 years: PSA * 4 ng/ml - 30 ng/ml - Men aged 65-75 years: PSA * 10 ng/ml- 30 ng/ml

Exclusion criteria

Exclusion criteria: all contra indications for MRI all contra indications for prostate biopsies protocol page 9

Design outcomes

Primary

Measure	Time frame
The number of patients with histological proven prostate cancer;	—

Secondary

Measure	Time frame
The number of patients with a different Gleason score after adding MRI-utrasound fusion-guided biopsies.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)